ReviewEndocrinology and metabolism (Seoul, Korea)2016
Insulin Secretory Capacity and Insulin Resistance in Korean Type 2 Diabetes Mellitus Patients.
Review in Endocrinology and metabolism (Seoul, Korea), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.Diabetes, obesity & metabolism · 2022 · on this mapTrial
- Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.Diabetes & metabolism journal · 2020Trial
- Clinical utility of 1-h post-load glucose in accelerating diagnosis of type 2 diabetes: a prospective cohort study.Acta diabetologica · 2026Article
- Metabolic heterogeneity at the onset of type 2 diabetes: phenotypes of insulin resistance and β-cell function in the Kazakh population.Frontiers in endocrinology · 2026Article
- Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes.Diabetes & metabolism journal · 2025Review
- Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulations.Diabetologia · 2025Article
- Reference Standards for C-Peptide in Korean Population: A Korean Endocrine Hormone Reference Standard Data Center Study.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective.Diabetes & metabolism journal · 2024Review
- The atherogenic index of plasma is associated with an increased risk of diabetes in non-obese adults: a cohort study.Frontiers in endocrinology · 2024Article
- Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition.Journal of diabetes investigation · 2021Review
- Article
- Article
- Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program.Journal of diabetes investigation · 2018 · on this mapObservational
- Articles in Endocrinology and Metabolism in 2016.Endocrinology and metabolism (Seoul, Korea) · 2017Article
- Insulin Resistance and Its Association with Metabolic Syndrome in Korean Children.BioMed research international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well known that many Korean patients with type 2 diabetes mellitus (T2DM) were non-obese and had decreased insulin secretion in past. However, during the past three decades, lifestyles in Korea have been westernized. As a result, the prevalence of obesity, the main cause of diabetes has increased. Thus, there is still a question as to whether the main pathophysiology of current Korean T2DM is insulin resistance or an insulin secretion defect. Because various anti-diabetes medications having different mechanisms of action are currently used as therapeutics, it is important to understand which of these factors is the main physiology in the development of diabetes in Koreans. In this review, we review changes in obesity prevalence, insulin resistance and insulin secretion defects in Korean T2DM during three decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.